title: Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents.
abstract: Percutaneous coronary intervention is the most commonly performed method of revascularizing obstructive coronary artery disease. The impact of stent strut design on clinical outcomes remains unclear. The Endeavour Resolute (ER-ZES) and the Resolute Integrity (RI-ZES) zotarolimus-eluting stents utilize identical polymers and anti-proliferative agents, differing only in their respective strut design. This study assessed the comparative safety and efficacy of these two stents in unrestricted contemporary real-world practice.
  
  
  METHODS
  A total of 542 patients were identified, corresponding to 340 ER-ZES and 480 RI-ZES. The primary endpoint was major adverse cardiac events (MACE) defined by a composite of death, nonfatal myocardial infarction and stroke. Secondary endpoints included post-procedural length of stay, in-stent restenosis, target lesion revascularization, target vessel revascularization, coronary artery bypass grafting and stent thrombosis.
  
  
  RESULTS
  MACE occurred in 3.2% of the ER-ZES cohort and 5.0% of the RI-ZES cohort (p= 0.43). Adjusted analysis utilizing propensity score-adjusted odds ratio for MACE, was 1.37 (95% CI 0.46-4.07, p=0.57). The mortality rate (0.9% ER-ZES vs. 1.9% RI-ZES, p=0.59), non-fatal MI (2.3% ER-ZES vs. 3.1% RI-ZES, p=0.75) and stroke (0.0% ER-ZES vs. 0.3% RI-ZES, p=0.85) were not different. Additionally, there was no difference in any of secondary outcomes.
  
  
  CONCLUSIONS
  The clinical performance and safety of both ER-ZES and RI-ZES were not statistically different, despite differences in stent strut design.
authors: . email@email.com.
authors: Pietro
authors: P
authors: Di Santo
authors: Trevor
authors: T
authors: Simard
authors: F Daniel
authors: FD
authors: Ramirez
authors: Ali
authors: A
authors: Pourdjabbar
authors: David T
authors: DT
authors: Harnett
authors: Kuljit
authors: K
authors: Singh
authors: Robert
authors: R
authors: Moreland
authors: Aun-Yeong
authors: AY
authors: Chong
authors: Alexander
authors: A
authors: Dick
authors: Marino
authors: M
authors: Labinaz
authors: Michael
authors: M
authors: Froeschl
authors: Michael
authors: M
authors: Froeschl
authors: Michael R
authors: MR
authors: Le May
authors: Derek Y
authors: DY
authors: So
authors: Benjamin
authors: B
authors: Hibbert
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000592:standards*; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000592:standards*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus